KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Net Cash Flow: 2010-2024

Historic Net Cash Flow for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Dec 2024 value amounting to -$5.7 million.

  • Supernus Pharmaceuticals' Net Cash Flow rose 139.72% to $8.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $121.1 million, marking a year-over-year increase of 291.35%. This contributed to the annual value of -$5.7 million for FY2024, which is 68.32% up from last year.
  • As of FY2024, Supernus Pharmaceuticals' Net Cash Flow stood at -$5.7 million, which was up 68.32% from -$18.1 million recorded in FY2023.
  • In the past 5 years, Supernus Pharmaceuticals' Net Cash Flow ranged from a high of $107.3 million in FY2020 and a low of -$110.3 million during FY2022.
  • Moreover, its 3-year median value for Net Cash Flow was -$18.1 million (2023), whereas its average is -$44.7 million.
  • As far as peak fluctuations go, Supernus Pharmaceuticals' Net Cash Flow spiked by 1,087.02% in 2020, and later tumbled by 179.44% in 2021.
  • Supernus Pharmaceuticals' Net Cash Flow (Yearly) stood at $107.3 million in 2020, then slumped by 179.44% to -$85.2 million in 2021, then declined by 29.47% to -$110.3 million in 2022, then soared by 83.62% to -$18.1 million in 2023, then surged by 68.32% to -$5.7 million in 2024.